Drugs / ASP0819
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03056690 | Mar 2017 → Feb 2018 | fibromyalgia | Astellas Pharma Global Development, Inc. | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP0819 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03056690 ↗ |
| Action | Activate | “ASP0819 is a novel, non-opioid KCa3.1 channel opener” PMID 33328761 ↗ Dec 2020 |
| Route | Oral | “15 mg/day of oral ASP0819” PMID 33328761 ↗ Dec 2020 |